Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia.
Author(s): Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, Fan X, Cather C, Goff DC
Affiliation(s): Massachusetts General Hospital Schizophrenia Program, 25 Staniford Street, 2nd Floor, Boston, MA 02114, USA. firstname.lastname@example.org
Publication date & source: 2011-08, Schizophr Res., 130(1-3):53-6. Epub 2011 May 11.
Publication type: Research Support, Non-U.S. Gov't
RATIONALE: Sedation is a common side effect of clozapine treatment and may exacerbate metabolic consequences of poor diet and exercise habits that are common in patients with schizophrenia. Modafinil has been proposed as a treatment for clozapine-induced sedation and metabolic abnormalities. OBJECTIVE: To estimate the effect sizes and person-to-person variation in anthropometric measures, glucose and lipid metabolism, and diet on modafinil treatment for future randomized control trials. METHODS: A double-blind, placebo-controlled, flexible-dosed 8-week pilot trial was conducted, adding modafinil up to 300 mg/day to stabilized schizophrenia outpatients receiving clozapine. Blood pressure, weight, BMI, laboratory assays, and dietary intake were tracked to monitor changes in metabolic markers. RESULTS: Thirty-five participants were randomly assigned to treatment with study drug or placebo and were included in the analysis. Modafinil did not improve blood pressure, weight, BMI, glucose or lipid metabolism compared to placebo. Modafinil was well tolerated and did not worsen psychosis. CONCLUSIONS: Results of this pilot trial do not support routine use of modafinil to counteract increased weight and metabolic diseases in patients taking clozapine. However, the effects of modafinil on weight and insulin regulation warrant further investigation with effect sizes of 0.4 to 0.6. Copyright (c) 2011 Elsevier B.V. All rights reserved.